Front Row Advisors’s State Street SPDR S&P Pharmaceuticals ETF XPH Stock Holding History
Bought
Maintained
Sold
Other funds holding XPH
KWM
FCBT
Front Row Advisors's XPH Position: Q1 2026 in Review
Front Row Advisors held its State Street SPDR S&P Pharmaceuticals ETF (XPH) position steady in Q1 2026 at 18 shares worth $978. The position accounts for ﹤0.01% of the portfolio, ranked #528.
Front Row Advisors first reported a position in XPH in Q1 2019 and has held it in 28 quarters since. The position peaked at $2K in Q3 2024. 82 funds tracked by Wall St. Rank hold XPH as of Q1 2026.
- Front Row Advisors held 18 shares of State Street SPDR S&P Pharmaceuticals ETF worth $978 as of Q1 2026.
- Front Row Advisors left its State Street SPDR S&P Pharmaceuticals ETF share count unchanged in Q1 2026.
- State Street SPDR S&P Pharmaceuticals ETF made up ﹤0.01% of Front Row Advisors's portfolio in Q1 2026, its #528 holding.
- Front Row Advisors first reported a position in State Street SPDR S&P Pharmaceuticals ETF in Q1 2019 and has held it in 28 quarters since.
- Front Row Advisors's State Street SPDR S&P Pharmaceuticals ETF position peaked at $2K in Q3 2024.
- 82 funds tracked by Wall St. Rank held State Street SPDR S&P Pharmaceuticals ETF as of Q1 2026.
Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.